Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales. This story matters for Finance & Markets readers tracking trade. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. Trade-News.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily trade signal